Search

Displaying results 8491 - 8500 of 10000 in total
  1. Drug

    VH3739937

    go.drugbank.com/drugs/DB25287
    Investigational

    VH3739937 is a small molecule drug. … VH3739937 is under investigation in clinical trial NCT06533280 (VH3739937 Phase 1 Multiple Ascending Dose (MAD) Study in Healthy Volunteers Including Relative Bioavailability (RBA), Optional Food Effect

  2. Drug

    SRD-001

    go.drugbank.com/drugs/DB25902
    Investigational

    SRD-001 is a biologic drug.

  3. Drug

    NBQ72S

    go.drugbank.com/drugs/DB26052
    Investigational

    NBQ72S is a small molecule drug. NBQ72S is under investigation in clinical trial NCT06810804 (A Phase IIa Study to Evaluate NBQ72S).

  4. Drug

    Unexpanded umbilical cord-derived allogeneic CD34- hematopoietic stem cells

    go.drugbank.com/drugs/DB28348
    Approved

    [L54106] Zemcelpro also contains [dorocubicel], a preparation CD34+ HSCs derived from the same cord blood sample and expanded _ex vivo_ using [UM-171]. … Unexpanded umbilical cord-derived allogeneic CD34- hematopoietic stem cells are one component of Zemcelpro, a cryopreserved allogeneic hematopoietic stem and progenitor cell therapy.

  5. Drug

    Whole Blood

    go.drugbank.com/drugs/DB28492
    Experimental

    Fresh Whole Blood is a biologic drug. Fresh Whole Blood is under investigation in clinical trial NCT03737669 (Mirasol Evaluation of Reduction in Infections Trial).

  6. Drug

    Lutetium Lu 177-DTPA-omburtamab

    go.drugbank.com/drugs/DB31015
    Investigational

    Lutetium Lu 177-DTPA-omburtamab is a radioimmunoconjugate made up of [omburtamab] conjugated with lutetium Lu 177 via the chelating agent of diethylenetriaminepentaacetic acid (DTPA).[L54566]

  7. Drug

    CX-052075

    go.drugbank.com/drugs/DB31655
    Approved

    CX-052075 is a nucleoside-modified messenger RNA (mRNA) encoding the N-terminal domain (NTD) and receptor-binding domain (RBD) of the spike glycoprotein of the SARS-CoV-2 Omicron variant sublineage LP.8.1 … spike protein, allowing for a more targeted immune response and the use of a significantly smaller amount of mRNA per dose.

  8. Drug

    FRAX597

    go.drugbank.com/drugs/DB31734
    Experimental

    FRAX597 is a small molecule drug that inhibits the p21-activated kinases (PAKs).[A274673, A274678]

    Categories: Heterocyclic Compounds, 1-Ring
  9. Drug

    Copper histidinate

    go.drugbank.com/drugs/DB32041
    Approved

    Menkes disease is a rare, X-linked recessive disorder caused by pathogenic variants in the ATP7A gene, which encodes a copper transport protein essential for absorbing dietary copper and transporting it … [A275383] Copper histidinate is a subcutaneously-administered copper-histidine complex that allows for copper supplementation in patients with defective ATP7A transporters.

  10. Drug

    IL21120033

    go.drugbank.com/drugs/DB32508
    Experimental

    IL21120033 is a first-in-class, small-molecule selective CXCR7 agonist.